跳至主要内容
临床试验/NCT00265330
NCT00265330已完成3 期

26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 169 人开始时间: 2006年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
169
试验地点
1
主要终点
Young Mania Rating Scale (YMRS) Total Score Change From Baseline

研究概览

简要总结

The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed)

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
10 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Participation in double-blind treatment study A1281132, meeting specific criteria of duration and safety

排除标准

  • Imminent risk of suicide or homicide, as judged by the site investigator;serious adverse event related to study medication in study A1281132; significant prolongation of QT interval in study A1281132.

研究组 & 干预措施

Open

Experimental

干预措施: Ziprasidone oral capsules (Drug)

结局指标

主要结局

Young Mania Rating Scale (YMRS) Total Score Change From Baseline

时间窗: baseline and 26 Weeks; 26 Weeks Last Observation Carried Forward (LOCF)

YMRS: 11-item instrument with scales 0 (normal) to 4 (highest abnormal)for 7 items and 0 (normal) to 8 (highest abnormal) for 4 items. Total possible 0 - 60. Baseline is from parent study A1281132.

Incidence of Lab Abnormalities

时间窗: Week 26

number of subjects with an abnormal lab value for those parameters with 5% or greater incidence of abnormality.

Change in Low-Density Lipoprotein (LDL) Cholesterol and Fasting Cholesterol

时间窗: Week 6, Week 26

Mean Change: lab value at observation minus lab value at baseline.

Change in Hormones

时间窗: Week 6, Week 26

Mean Change: lab value at observation minus lab value at baseline

Mean Change From Baseline in Supine Systolic Blood Pressure

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Clinical Global Impression of Severity (CGI-S) Change From Baseline

时间窗: baseline and 26 Weeks; 26 Weeks LOCF

CGI-S Scale:standardized assessment tool to rate severity of subject's illness; assesses investigator's impression of subject's current illness state. Change: score at observation minus score at baseline. Score: 1 (not ill at all) to 7 (among most extremely ill). Baseline = last available observation from parent double-blind study(A1281132).

Mean Change From Baseline in Supine Diastolic Blood Pressure

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Mean Change From Baseline in Supine Pulse Rates

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Mean Change From Baseline in Standing Diastolic Blood Pressure

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Mean Change From Baseline for Body Weight

时间窗: Week 6, Week 26

Mean change; body weight value at observation minus body weight value at baseline.

Body Mass Index (BMI) Z-score Frequency

时间窗: Week 26

change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change

Mean Change From Baseline for QTcF Intervals

时间窗: Baseline to Week 26 (end of study)

QT intervals (observed in an electrocardiogram)corrected using Fridericia's formula (QTcF). Mean change: mean change of observation minus baseline. Baseline: last available observation in the parent double-blind study.

Mean Change From Baseline in Standing Systolic Blood Pressure

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Mean Change From Baseline in Standing Pulse Rates

时间窗: Week 1 through Week 26

Mean Change: vital sign value at observation minus vital sign value at baseline

Frequency of Largest Categorical Increases in QTcF for Males

时间窗: Week 26 (end of study)

QT intervals (observed in an electrocardiogram) corrected with Fridericia's Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.

Frequency of Largest Categorical Increases in QTcF - All Subjects

时间窗: Week 26 (end of study)

QT intervals (observed in an electrocardiogram)corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.

Mean Change From Baseline for Body Mass Index (BMI) Z-Score

时间窗: Week 6, 26, early termination

mean change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change

Frequency of Largest Categorical Increases in QTcF for Females

时间窗: Week 26 (end of study)

QT interval (observed in an electrocardiogram) corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.

次要结局

未报告次要终点

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验